Guggenheim Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Guggenheim Capital’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-58,303	Closed	-$177K	–	1720
2024 Q4	$177K	Sell	58,303 -569	-1%	-$2.48K	﹤0.01%	1611
2024 Q3	$306K	Buy	+58,872	New	+$293K	﹤0.01%	1609
2022 Q4	–	Sell	-32,735	Closed	-$884K	–	2011
2022 Q3	$884K	Sell	32,735 -1,823	-5%	-$37K	0.01%	1199
2022 Q2	$478K	Sell	34,558 -2,247	-6%	-$34.6K	﹤0.01%	1602
2022 Q1	$718K	Buy	36,805 +1,043	+3%	+$15.8K	﹤0.01%	1520
2021 Q4	$583K	Buy	35,762 +158	+0.4%	+$2.63K	﹤0.01%	1615
2021 Q3	$992K	Sell	35,604 -827	-2%	-$23.6K	0.01%	1419
2021 Q2	$1.08M	Buy	36,431 +1,667	+5%	+$48.1K	0.01%	1449
2021 Q1	$972K	Buy	34,764 +16,578	+91%	+$459K	0.01%	1413
2020 Q4	$515K	Buy	+18,186	New	+$471K	﹤0.01%	1629

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Guggenheim Capital's RVNC Position: Q1 2025 in Review

Guggenheim Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 58,303 shares — an estimated $177K sold.

Guggenheim Capital first reported a position in RVNC in Q4 2020 and held it in 10 quarters. The position peaked at $1.08M in Q2 2021. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Guggenheim Capital reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Guggenheim Capital sold 58,303 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $177K.
Guggenheim Capital first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 10 quarters.
Guggenheim Capital's Revance Therapeutics, Inc. position peaked at $1.08M in Q2 2021.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Guggenheim Capital's 13F filing for Q1 2025, filed 14 May 2025.